Avinger

Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat. The company was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avinger reports Q1 revenue growth, secures China partnership for expansion

Avinger's Q1 2024 performance showed revenue growth but challenges in profitability.
Strategic partnerships and product development present growth opportunities.
Financial restructuring and cost management are crucial for future success.

Avinger reports improved Q3 performance and strategic growth initiatives

Avinger's Q3 2024 performance showed operational improvements and cost-saving initiatives, leading to reduced losses.
The company's strategic partnerships and focus on innovation position them for growth opportunities in the medical device market.
While challenges persist, Avinger's progress in commercialization and partnerships signal a path towards financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avinger (NASDAQ:AVGR) reported Q4 results on Thursday afternoon. Quarterly Results Earnings per share were up 87.93% over the past year to ($0.07), which missed the estimate of ($0.06).

Avinger: Q4 Earnings Insights

19% Sequential Increase in Total Revenue Tigereye™ Drives 38% Sequential Growth in Image-Guided CTO Revenue REDWOOD CITY, CA / ACCESSWIRE / March 11, 2021 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the fourth quarter ended December 31, 2020. Fourth Quarter and Recent Highlights Revenue increased 19% sequentially to $2.7 million, the highest level in 3 years Image-guided CTO revenue increased 38% sequentially, driven by limited launch of the new Tigereye™ device Gross margin rose sequentially to 36%, reflecting increased sales activity and cost efficiency  Opened 9 new Lumivascular accounts in the fourth quarter, bringing total new accounts for the full year to 36 Progressed Tigereye to full commercial launch in January 2021, following successful limited launch in the fourth quarter Improved the terms of Avinger's existing loan agreement in January 2021, including the extension of the maturity date to 2025 Ended December 31, 2020 with cash on hand of $22.2 million and added approximately $13 million in net proceeds from a common stock offering in February 2021 Jeff Soinski, Avinger's President and CEO, commented, "Avinger remains focused on driving top-line growth by introducing new products, launching new accounts and expanding utilization at existing sites.

Avinger Reports Fourth Quarter 2020 Financial Results

REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that Mark Weinswig, CFO, will be attending the Q1 Virtual Investor Summit. Management will conduct an overview presentation available on the investor relations section of Avinger's website,  www.avinger.com , and be available for one-on-one investor meetings throughout the day.

Avinger, Inc. to Present at the Q1 Virtual Investor Summit

REDWOOD CITY, CA / ACCESSWIRE / March 2, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.

Avinger to Announce Fourth Quarter Full Year 2020 Results on March 11, 2021

Avinger (AVGR) stock is on the rise Thursday despite there being no new news from the company but chatter about a patent on social media. The post AVGR Stock: The Social Media Buzz That Has Avinger Shares Soaring appeared first on InvestorPlace.

AVGR Stock: The Social Media Buzz That Has Avinger Shares Soaring

The stock price of Avinger Inc (NASDAQ: AVGR) is trading at over 60% pre-market as of 6:09 AM ET. This is why it happened.

AVGR Stock Price Increases Over 60% Pre-Market: Why It Happened

19 New U.S. and International Patents Issued and Allowed in 2020 REDWOOD CITY, CA / ACCESSWIRE / January 19, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the expansion of its intellectual property portfolio in 2020. Avinger announced the issuance and allowance of 10 new patents in the U.S. and 9 new patents in international markets in 2020, including 7 new patents related to its recently introduced Tigereye™ image-guided CTO crossing catheter.

Avinger Expands Intellectual Property Portfolio

The stock price of Avinger Inc (NASDAQ: AVGR) increased by 32.43% on January 15. This is why it happened.

AVGR Stock Price Increased 32.43%: Why It Happened

Avinger (AVGR) stock is taking off on Friday after announcing the full commercial release of its Tigereye medical device. The post AVGR Stock: 11 Things to Know About Avinger as Shares Rocket Higher appeared first on InvestorPlace.

AVGR Stock: 11 Things to Know About Avinger as Shares Rocket Higher

REDWOOD CITY, CA / ACCESSWIRE / January 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced full commercial launch of its Tigereye™ image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany are now able to order the Tigereye device.

Avinger Initiates Full Commercial Launch of Tigereye(TM) Image-Guided CTO Crossing Catheter

Avinger (AVGR) is seeing a massive boost to its stock on Friday after being listed as a hot penny stock to buy on Robinhood. The post AVGR Stock: 6 Things to Know About ‘Robinhood's Hot Penny Stock to Buy' Avinger appeared first on InvestorPlace.

AVGR Stock: 6 Things to Know About ‘Robinhood's Hot Penny Stock to Buy' Avinger

REDWOOD CITY, CA / ACCESSWIRE / January 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its executive team will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021.

Avinger to Participate in HC Wainwright Conference

The stock price of Avinger Inc (NASDAQ: AVGR) increased by 65.48% this past month. This is why it happened.

AVGR Stock Price Increased 65.48% This Month: Why It Happened

REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split, and to adjourn the Annual Meeting for the purpose of continuing to solicit votes with respect to the proposals presented.

Avinger Announces Annual Meeting Results

Avinger's (AVGR) CEO Jeff Soinski on Q3 2020 Results - Earnings Call Transcript

Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Avinger (AVGR) Upgraded to Buy: Here's What You Should Know

Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Avinger (AVGR) Upgraded to Buy: Here's Why

Avinger (AVGR) news for Friday concerning approval from the FDA for one of its medical devices has AVGR stock on the move.
The post Avinger News: AVGR Stock Down 8% Following FDA Approval appeared first on InvestorPlace.

Avinger News: AVGR Stock Down 8% Following FDA Approval

Avinger's (AVGR) CEO Jeff Soinski on Q2 2020 Results - Earnings Call Transcript

Bioline RX

Proteostasis Therapeutics

Vaccinex Inc

Viveve Medical

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Bet on Rising Price-to-Earnings With 5 Top Stocks

Carriage Services

Mogo

PolarityTE Inc

Teekay Tankers

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks

Guardion Health Sciences Inc

KAR Auction Services

There are pockets of the stock market that look far too overvalued to ignore, and our deep learning algorithms paired with our Artificial Intelligence (“AI”) technology has identified the top short targets for today.

Top Companies To Short In A Potentially Overbought Market

Avinger (AVGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Avinger (AVGR) Upgraded to Strong Buy: Here's Why

Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2020 Results - Earnings Call Transcript

News for Avinger Stock (AVGR)